Tesamorelin (10mg) About This Product
Tesamorelin (10 mg) is a synthetic peptide supplied as a lyophilized powder for controlled laboratory and preclinical research. Tesamorelin is a stabilized analog of endogenous human growth hormone–releasing hormone (GHRH) and is studied for its ability to stimulate endogenous growth hormone (GH) secretion and downstream metabolic signaling pathways.
Structurally, Tesamorelin is a 44–amino acid peptide derived from native GHRH, incorporating a modified N-terminus (trans-3-hexenoic acid) that enhances resistance to enzymatic degradation and supports extended functional stability compared with unmodified GHRH.
In endocrine and metabolic research, Tesamorelin has been examined in studies of visceral adipose tissue (VAT), lipid metabolism, hepatic fat content, and the GH/IGF-1 axis. Laboratories that buy tesamorelin peptide commonly use the 10 mg vial format to prepare solutions within dosing ranges evaluated in translational research protocols.
Tesamorelin (10mg) Key Features and Benefits
- Amino acid sequence (44 aa): Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
(“Unk” denotes the N-terminal trans-3-hexenoic acid modification) - Peptide class: Stabilized GHRH analog
- Molecular formula: C₂₂₃H₃₇₀N₇₂O₆₉S
- Molecular weight: 5,195.908 g/mol
- CAS number: 901758-09-6
- PubChem CID: 44147413
- Format: High-purity, lyophilized peptide
Tesamorelin (10mg) Mechanism & Research Applications
Tesamorelin acts through the growth hormone–releasing hormone receptor (GHRHR), a Class B G protein–coupled receptor expressed on anterior pituitary somatotrophs.
Receptor engagement initiates:
- Adenylate cyclase activation
- Increased intracellular cAMP
- Protein kinase–mediated phosphorylation cascades
- Regulated gene-expression programs linked to GH synthesis and release
This mechanism supports physiologic, pulsatile GH secretion, preserving endocrine feedback regulation while allowing detailed study of GH/IGF-1 signaling kinetics in experimental systems.
Tesamorelin is supplied exclusively for laboratory research and is used in:
- GHRHR pharmacology: Ligand binding and potency assays
- Second-messenger studies: cAMP-linked signaling and downstream phosphorylation
- GH/IGF-1 axis mapping: In vitro and in vivo pathway analysis
- Endocrine feedback research: Signaling kinetics and regulatory loops
- Metabolic and adiposity studies: VAT, lipid profiles, and hepatic fat metrics
- Exploratory biomarker workflows: IGF-1 and metabolic marker evaluation
Exploratory investigations of cognitive or neurologic outcomes have been reported in limited datasets and are not considered a primary research focus.
Tesamorelin (10mg) Dosing & Observed Effects in Research
Published clinical studies most commonly evaluated 2 mg once-daily subcutaneous dosing over 12 weeks to 12 months. The 10 mg research vial supports dose-response modeling, longitudinal endocrine studies, and preparation of daily-dosing solutions consistent with published protocols.
Visceral Adipose Tissue (VAT) Findings
Across controlled studies, 69–72% of tesamorelin-treated subjects achieved clinically significant VAT reduction (≥8%) at 26 weeks. Mean VAT reductions of 15–20% were reported in responders, alongside consistent increases in circulating IGF-1 reflecting enhanced GH axis activity.
Metabolic Observations
Studies evaluating lipid parameters reported improvements in triglycerides and HDL cholesterol in some populations. Visceral fat reaccumulation was observed following discontinuation, a factor frequently addressed in experimental design and interpretation.
Preclinical and translational research involving Tesamorelin includes:
- Visceral adiposity and lipid biomarker studies
- Endocrine axis research in chronic infection and metabolic models
- GH-mediated metabolic regulation and feedback signaling
- Neuroendocrine biomarker readouts linked to GH/IGF-1 dynamics
Tesamorelin (10mg) Storage, Safety & References
- Lyophilized (unopened):
- –80 °C: Preferred for 1+ year storage
- –20 °C: Long-term stability
- 2–8 °C: Short handling periods only
- Reconstitution:
- Use sterile aqueous buffer at pH 7.2–7.4
- Store at 2–8 °C
- Stability 14–30 days, depending on diluent
- Avoid freeze–thaw cycles; single-use aliquots are recommended
- Visual inspection: White powder expected; reconstituted solution should be clear
Handle using standard laboratory precautions, including PPE, and avoid inhalation, ingestion, or accidental injection. Dispose of materials in accordance with institutional and regulatory requirements. Qualified laboratories that order tesamorelin peptide must ensure full compliance with research-use regulations.
References
https://pubmed.ncbi.nlm.nih.gov/18057338
https://pubmed.ncbi.nlm.nih.gov/22495074
https://pubmed.ncbi.nlm.nih.gov/25038357
https://pmc.ncbi.nlm.nih.gov/articles/PMC5633509
https://pubmed.ncbi.nlm.nih.gov/20943777
Compliance Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use.